The Journal of Nuclear Medicine最新文献

{"title":"Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study","authors":"Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, Yi Cai","doi":"10.2967/jnumed.124.269189","DOIUrl":"https://doi.org/10.2967/jnumed.124.269189","url":null,"abstract":"<p>Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [⁶⁸Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [⁶⁸Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [⁶⁸Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [⁶⁸Ga]Ga-PSMA-617 PET/CT remains underexplored. <strong>Methods:</strong> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [⁶⁸Ga]Ga-RM26 PET/CT and [⁶⁸Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <strong>Results:</strong> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [⁶⁸Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [⁶⁸Ga]Ga-PSMA-617 PET/CT. [⁶⁸Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [⁶⁸Ga]Ga-PSMA-617 PET/CT. The combined use of [⁶⁸Ga]Ga-RM26 PET/CT and [⁶⁸Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [⁶⁸Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [⁶⁸Ga]Ga-PSMA-617 PET/CT. [⁶⁸Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [⁶⁸Ga]Ga-PSMA-617 PET/CT. The combined [⁶⁸Ga]Ga-RM26 and [⁶⁸Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <strong>Conclusion:</strong> In dual-target imaging, [⁶⁸Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [⁶⁸Ga]Ga-RM26 PET/CT and [⁶⁸Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning","authors":"Carlos Vinícius Gomes, Yizhou Chen, Isabel Rauscher, Song Xue, Andrei Gafita, Jiaxi Hu, Robert Seifert, Lorenzo Mercolli, Julia Brosch-Lenz, Jimin Hong, Marc Ryhiner, Sibylle Ziegler, Ali Afshar-Oromieh, Axel Rominger, Matthias Eiber, Thiago Viana Miranda Lima, Kuangyu Shi","doi":"10.2967/jnumed.124.268175","DOIUrl":"https://doi.org/10.2967/jnumed.124.268175","url":null,"abstract":"<p>Single-time-point (STP) image-based dosimetry offers a more convenient approach for clinical practice in radiopharmaceutical therapy (RPT) compared with conventional multiple-time-point image-based dosimetry. Despite numerous advancements, current STP methods are limited by the need for strict and late timing in data acquisition, posing challenges in routine clinical settings. This study introduces a new concept of instant STP (iSTP) dosimetry, achieved by predicting the effective half-life (<I>T</I><SUB>eff</SUB>) of organs using machine learning applied on pretherapy patient data (PET and clinical values). <b>Methods:</b> Data from 22 patients who underwent pretherapy ⁶⁸Ga-gallium <I>N</I>,<I>N</I>-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-<I>N</I>,<I>N</I>-diacetic acid ([⁶⁸Ga]Ga-PSMA-11) imaging and subsequently [¹⁷⁷Lu]Lu-PSMA I&amp;T RPT were analyzed. A machine learning model was developed for <I>T</I><SUB>eff</SUB> predictions for the left and right kidneys, liver, and spleen subsequently used to estimate time-integrated activity and absorbed dose. iSTP results were compared against multiple-time-point and previously proposed H&auml;nscheid methods. Our method comprised 2 different prediction scenarios, using data before each therapy cycle and from the first cycle. <b>Results:</b> The iSTP method introduced early posttherapy time points (2, 20, 43, and 69 h) for the left kidney, right kidney, liver, and spleen. Dosimetry in the first scenario, aggregating 2 and 20 h, achieved mean differences in time-integrated activity below 27% for all organs. To assess the feasibility, these time points were compared with the best results from the H&auml;nscheid method (kidneys, 69 h; liver and spleen, 20 h). At 2 h, a significant difference (<I>P</I> &lt; 0.001) was found for almost all organs except for the spleen (<I>P</I> = 0.1370). However, at 20 h, no significant differences were found for the right kidney, liver, and spleen, apart from the left kidney (<I>P</I> &lt; 0.01). In the scenario using only the initial PET/CT data to predict <I>T</I><SUB>eff</SUB> for subsequent cycles, iSTP dosimetry achieved no statistical significance (<I>P</I> &gt; 0.05) for all cycles in comparison to results using PET data before each therapy cycle. <b>Conclusion:</b> Our preliminary results prove the concept for prediction of <I>T</I><SUB>eff</SUB> with pretherapy data and achieving STP shortly and flexibly after the RPT. The proposed method may expedite the application of dosimetry in broader contexts, such as outpatient or short-duration inpatient treatment.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143666003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dansylated Amino Acid–Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics","authors":"Hongzhang Yang, Jiarou Wang, Xuejun Wen, Huifeng Guo, Vivianne Jakobsson, Tianzhi Zhao, Fantian Zeng, Huaxiang Shen, Heng Zhang, Xiaomin Liu, Yatong Qin, Xinyi Li, Hehe Xiong, Zijian Zhou, Jingjing Zhang, Xiaoyuan Chen","doi":"10.2967/jnumed.124.268959","DOIUrl":"https://doi.org/10.2967/jnumed.124.268959","url":null,"abstract":"&lt;p&gt;Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy has demonstrated promising potential for treating metastatic castration-resistant prostate cancer. Recently, albumin-binding motif-modified PSMA radioligands with prolonged blood circulation were developed to improve tumor uptake and therapeutic effectiveness, properties which, however, were associated with an increased risk of bone marrow toxicity. This study presents new PSMA-targeted radioligands incorporating dansylated amino acids as relatively weak and preferable albumin binders to achieve a fine balance between increased tumor accumulation, safety, and diagnostic efficacy, facilitating a unified approach to theranostics within a single molecular framework. &lt;strong&gt;Methods:&lt;/strong&gt; Three novel PSMA ligands ([&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Dan-Gly-PSMA, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Dan-Nva-PSMA, and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Dan-Phe-PSMA, denoted as [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-LNC1011) were synthesized with dansylated amino acids and measured the albumin-binding properties with human serum albumin through ultrafiltration experiments. Binding affinity and PSMA-targeting specificity were investigated using a saturation binding assay and cell uptake in the PSMA-induced prostate cancer 3 cell line (PC3-PIP). PET imaging in PC3-PIP tumor–bearing mice was performed to evaluate the preclinical pharmacokinetics and diagnostic efficiency of &lt;sup&gt;68&lt;/sup&gt;Ga-labeled PSMA ligands. Tumor uptake of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LNC1011 was evaluated through SPECT/CT imaging and biodistribution studies. Radiopharmaceutical therapy studies were conducted to systematically assess the therapeutic effect of the radioligand. &lt;strong&gt;Results:&lt;/strong&gt; Three novel PSMA radioligands ([&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Dan-Gly-PSMA, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Dan-Nva-PSMA, and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-LNC1011) with various dansylated amino acids were successfully synthesized with a radiochemical yield greater than 97%. In the PC3-PIP xenograft tumor model, the tumor/heart, tumor/liver, tumor/kidney, and tumor/muscle ratios were 9.82 ± 2.35, 12.42 ± 3.71, 4.36 ± 0.29, and 52.88 ± 12.08 at 4 h after injection, respectively. Biodistribution studies confirmed the significantly higher tumor uptake of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LNC1011 (127.36 ± 16.95 %ID/g) over [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 (17.44 ± 6.29 %ID/g) at 4 h after injection, and no decrease was measured for the [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LNC1011 at up to 72 h after injection, which was corroborated with SPECT imaging. A single injection of 9.3 MBq of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LNC1011 achieved 89.43% inhibition of tumor growth, equivalent to 18.5 MBq of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 (90.87%). [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-LNC1011 PET/CT scans of patients with metastatic castration-resistant prostate cancer identified as many lesions as [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 did, confirming its diagnostic efficacy. &lt;strong&gt;Conclusion:&lt;/strong&gt; &lt;sup&gt;68&lt;/sup&gt;Ga/&lt;sup&gt;177&lt;/sup&gt;Lu-LNC1011, characterized by high tumor uptake and retention alo","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging","authors":"Verena Pichler, Verena Schwingenschlögl-Maisetschläger, Irem Duman, Xavier Monforte, Stefanie Ponti, Lukas Zimmermann, Elma Joldic, Monika Dumanic, Chrysoula Vraka, Marcus Hacker, Christian Kraule, Andreas Herbert Teuschl-Woller","doi":"10.2967/jnumed.124.269133","DOIUrl":"https://doi.org/10.2967/jnumed.124.269133","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269133absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check","authors":"Ronald Boellaard, Gerben J.C. Zwezerijnen, Irène Buvat, Laurence Champion, Narinée Hovhannisyan-Baghdasarian, Fanny Orlhac, Anne I.J. Arens, Daphne Lobeek, Filiz Celik, Cristina Mitea, Julia E. Huijbregts, Nelleke Tolboom, Bart de Keizer, Roelf Valkema, Floris H.P. van Velden, Petra Dibbets-Schneider, Sanne E. Wiegers, Pieternella J. Lugtenburg, Sally F. Barrington, Josée M. Zijlstra","doi":"10.2967/jnumed.124.269271","DOIUrl":"https://doi.org/10.2967/jnumed.124.269271","url":null,"abstract":"<p>Measuring total metabolic tumor volume (TMTV) on ¹⁸F-FDG PET/CT images in clinical practice requires a fast, reliable, and easy-to-perform multilesional segmentation workflow. We conducted a field test to derive total metabolic volumes using 5 representative baseline ¹⁸F-FDG PET/CT scans from patients with diffuse large B-cell lymphoma. The scans were transferred to 10 different sites or readers who used different commercially available software platforms to derive TMTV after a recently proposed benchmark workflow. Observed TMTVs were compared with reference values, and overall analysis times were reported. Our results show that TMTVs can be obtained with reasonable accuracy across readers and platforms (within 10% compared with reference benchmark values for most TMTVs) but that processing times can vary considerably depending on reader experience and the software platform. Our study showed that there is an urgent need to improve TMTV segmentation workflows in clinical practice, requiring closer collaboration between users and software vendors.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [18F]FDG and [68Ga]Ga-PSMA in PET/CT","authors":"Cláudia S. Constantino, Francisco P.M. Oliveira, Marisa Machado, Susana Vinga, Durval C. Costa","doi":"10.2967/jnumed.124.269067","DOIUrl":"https://doi.org/10.2967/jnumed.124.269067","url":null,"abstract":"<p>This study investigated the added value of using maximum-intensity projection (MIP) images for fully automatic segmentation of lesions using deep learning (DL) in [¹⁸F]FDG and [⁶⁸Ga]Ga-prostate-specific membrane antigen (PSMA) PET/CT scans. <strong>Methods:</strong> We used 489 staging [¹⁸F]FDG PET/CT scans from patients diagnosed with melanoma, lymphoma, or lung cancer (391 scans for training and 98 for internal testing). As an external test set, 117 staging [¹⁸F]FDG PET/CT scans from lymphoma patients (another center, 2 scanners) were used. For [⁶⁸Ga]Ga-PSMA, 355 whole-body [⁶⁸Ga]Ga-PSMA PET/CT scans from patients with prostate cancer were used (285 scans for training and 70 scans for testing). All scans had corresponding expert-based segmentation (ground truth). Three approaches per radiopharmaceutical were used for fully automatic segmentation: 3-dimensional U-Net applied directly on PET images (standard-DL–based), 3-dimensional U-Net applied on multiangle MIP images (MIP-DL–based), and a combined approach (standard-DL+MIP-DL–based). The performance was evaluated in comparison with ground truth segmentation through lesion detection scores, voxelwise segmentation overlap metrics, and quantification of clinically relevant imaging features. <strong>Results:</strong> For [¹⁸F]FDG PET scans, the MIP-DL–based method showed a lower lesion false-discovery rate than did the standard-DL–based approach, although not significant in internal and external test sets. Sensitivity in lesion detection did not vary significantly, and a reduction in voxelwise metrics was observed (median Dice coefficient of 0.65 vs. 0.80 in the internal test set). Significantly increased performance was obtained with the combined approach in both test sets. In the internal test set, the median false-discovery rate was 0% (12% using the standard-DL), and a considerable increase in the agreement of lesion features was observed (intraclass correlation coefficient range, 0.42–0.94 for standard-DL–based and 0.80–0.94 for the combined approach). Similar results were observed in the external set. Regarding [⁶⁸Ga]Ga-PSMA scans, there was no significant increase in the performance of MIP-DL–based and combined approaches compared with standard-DL, which was already outstanding in lesion detectability. <strong>Conclusion:</strong> Fully automatic segmentation of lesions in whole-body or total-body [¹⁸F]FDG PET/CT scans may benefit from the addition of the MIP-DL–based segmentation compared with the standard-DL–based method. It reduces the number of false-positive lesions and improves the patients’ tumor burden quantification. In [⁶⁸Ga]Ga-PSMA PET/CT scans, no benefits were observed compared with standard-DL–based segmentation.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Dose–Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET","authors":"Alexandros Moraitis, Andre Prochnow, Thorsten Dirk Poeppel, Jochen Schmitz, Christina Laschinsky, Ken Herrmann, Andreas Bockisch, Pedro Fragoso Costa, David Kersting, Walter Jentzen","doi":"10.2967/jnumed.124.269377","DOIUrl":"https://doi.org/10.2967/jnumed.124.269377","url":null,"abstract":"<p>[¹³¹I]Metaiodobenzylguanidine (MIBG) therapy in patients with neural crest tumors has demonstrated sustained control of catecholamine-associated hypertension and corresponding partial response. Details on how neural crest tumors respond to an absorbed dose delivered by [¹³¹I]MIBG-targeted therapies is insufficiently known. The primary aim of this retrospective study was to assess the tumor dose–response relationship by means of quantitative analysis of [¹²⁴I]MIBG PET data. <strong>Methods:</strong> The tumor dose–response relationship was studied in patients with advanced malignant pheochromocytoma, neuroblastoma, or paraganglioma receiving [¹³¹I]MIBG treatment, as well as pretherapeutic and follow-up [¹²⁴I]MIBG-based dosimetry. [¹²⁴I]MIBG PET imaging was performed around 4, 24, 48, and 120 h after injection. Lesion uptake was projected to [¹³¹I]MIBG for every time point, and respective time-integrated activity coefficients (TIACs) for [¹³¹I]MIBG were calculated and used for tumor-absorbed dose estimation. Functional response was denoted for decrease of maximal lesion uptake or TIAC by at least 30% in the follow-up examination. In a consecutive analysis, the predictive value of a single tumor-uptake assessment from PET imaging at 24 h after administration was investigated with respect to receiving the derived target dose. <strong>Results:</strong> In total, 46 lesions from 9 patients were available for dose–response analysis. The mean ± SD tumor-absorbed dose coefficient was 13.4 ± 15.4 Gy/GBq (median, 7.2 Gy/GBq; range, 1.1–64.7 Gy/GBq). A high correlation (−0.60, <em>P</em> &lt; 0.001) was found between uptake decrease and tumor dose. In addition, a very high correlation (0.91, <em>P</em> &lt; 0.001) was found between uptake and TIAC decrease. The estimated targeted tumor dose was 200 Gy, that is, the dose at which the response rate exceeded the 90% threshold. A single 24-h uptake assessment showed predictive value with respect to receiving the target dose. <strong>Conclusion:</strong> This study demonstrated a clear correlation between tumor-absorbed dose and functional response in [¹³¹I]MIBG therapy and proposes a target dose for response at the tumor level.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer","authors":"Kjetil Berner, Eivor Hernes, Monika Kvassheim, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L. Bakken, Simen R. Grønningsæter, Øyvind S. Bruland, Roy H. Larsen, Lily Bouzelmat, Vicki L. Jardine, Caroline Stokke","doi":"10.2967/jnumed.124.269299","DOIUrl":"https://doi.org/10.2967/jnumed.124.269299","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269299absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Metaanalysis","authors":"Ashwin Singh Parihar, Sofia Vaz, Siobhan Sutcliffe, Niharika Pant, Jan W. Schoones, Gary A. Ulaner","doi":"10.2967/jnumed.124.269163","DOIUrl":"https://doi.org/10.2967/jnumed.124.269163","url":null,"abstract":"<p>¹⁸F-fluoroestradiol (¹⁸F-FES) PET/CT has been investigated as a potential biomarker to predict response to endocrine therapies in patients with estrogen receptor (ER)–positive breast cancer. Although previous findings were promising, most had limited statistical significance because of small individual sample sizes. Therefore, we performed a systematic review and metaanalysis of the ¹⁸F-FES PET/CT literature to increase our power to evaluate the utility of ¹⁸F-FES PET/CT as a biomarker for prediction of clinical benefit from endocrine therapy in patients with ER-positive breast cancer. <strong>Methods:</strong> A comprehensive literature search was conducted across multiple databases, including PubMed, MEDLINE via OVID, Embase, Web of Science, Emcare, and the Cochrane Central Register of Controlled Trials through November 1, 2024, for studies that included patients with ER-positive breast cancer who received an ¹⁸F-FES PET/CT at baseline and received subsequent endocrine therapy. For each eligible study, data were extracted using a predesigned data extraction form. Random effects models were used to estimate the likelihood of clinical benefit from endocrine therapy after a positive ¹⁸F-FES PET scan, the likelihood of clinical benefit from endocrine therapy after a negative ¹⁸F-FES PET scan, and the risk ratio of clinical benefit from endocrine therapy comparing those who were ¹⁸F-FES–positive to those who were ¹⁸F-FES–negative. <strong>Results:</strong> From 1,105 database records retrieved, 12 studies were included in the metaanalysis (<em>n</em> = 308 participants with data on ¹⁸F-FES PET results and response to endocrine therapy). The likelihood of clinical benefit after a positive ¹⁸F-FES PET scan was 66% (95% CI, 51%–79%; <em>I</em>² = 76.6%; <em>n</em> = 227 participants) and the likelihood after a negative ¹⁸F-FES PET scan was 11% (95% CI, 3.5%–22%; <em>I</em>² = 0.0%; <em>n</em> = 81 participants). The risk ratio of response that compared those who were ¹⁸F-FES–positive with those who were ¹⁸F-FES–negative was 3.21 (95% CI, 1.96–5.25; <em>I</em>² = 0.0%; <em>P</em> &lt; 0.0001). <strong>Conclusion:</strong> ¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive breast cancer. There is strong evidence that patients with ¹⁸F-FES–negative disease are unlikely to derive clinical benefit from endocrine therapies, despite the presence of ER-positive disease on pathology. This supports a role for ¹⁸F-FES PET in identifying patients for whom endocrine therapy may or may not be an appropriate treatment option.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System","authors":"Edwin C. Pratt, Travis M. Shaffer, David Bauer, Jason S. Lewis, Jan Grimm","doi":"10.2967/jnumed.124.268806","DOIUrl":"https://doi.org/10.2967/jnumed.124.268806","url":null,"abstract":"<p>Cerenkov (or Cherenkov) luminescence occurs when charged particles exceed the phase velocity of a given medium. Cerenkov as a modality has gained interest for visualization of numerous radionuclides. However, reported Cerenkov intensities are limited or provided as theoretic fluence estimates. Here, we present the largest experimental dataset of Cerenkov-emitting radionuclides using the in vivo imaging system (IVIS Spectrum). We report Cerenkov radiances for 23 Cerenkov-emitting radionuclides, covering electrons, α-particles, and β-particles purified and in equilibrium where appropriate. Radionuclides measured include ¹¹C, ¹⁸F, ³²P, ⁴⁷Sc, ⁵²Mn, ⁶⁴Cu, ⁶⁷Cu, ⁶⁸Ga, ⁷²As, ⁷⁶Br, ⁸⁶Y, ⁸⁹Zr, ⁹⁰Y, ¹²⁴I, ¹³¹I, ¹³⁴Ce, ¹⁶¹Tb, ¹⁷⁷Lu, ²⁰³Pb, ²¹²Pb, ²²³Ra, ²²⁵Ac, and ²²⁷Th. These radiances allow experimental comparisons of radionuclides in Cerenkov luminescence imaging studies in the visible emission window, alongside minimum detectable activity concentrations. Lastly, these values greatly agree with prior theoretic modeling estimates.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}